Enda Monitor Pediatric Glucocorticoid

---
name: enda-monitor-pediatric-glucocorticoid
description: This skill outlines monitoring glucocorticoid replacement in children with primary adrenal insufficiency (PAI) using clinical assessment of growth velocity, weight, blood pressure, and energy levels. Trigger when evaluating a child with PAI for adequacy of glucocorticoid therapy during routine follow-up.
---

# Monitor Glucocorticoid Replacement in Children via Growth Velocity, Weight, Blood Pressure, and Energy Levels

## STEP 1 — Gather Information
Measure height and calculate growth velocity (cm/year), record weight, assess blood pressure (sitting and standing), and query energy levels/activity/fatigue or lethargy. Record these parameters for trend analysis.

## STEP 2 — Rule In / Rule Out
Determine if there is evidence of glucocorticoid under-replacement (e.g., declining growth velocity, weight loss or poor weight gain, fatigue, postural hypotension, hyperpigmentation). If yes, proceed to evaluate for dose increase; if no, proceed to evaluate for over-replacement.

## STEP 3 — Classify or Stratify
Classify the clinical picture: under-replacement suggests need for dose increase; over-replacement (e.g., excessive weight gain, insomnia, peripheral edema, hypertension, Cushingoid features) suggests need for dose decrease; stable parameters indicate current dose is appropriate.

## STEP 4 — Decide
Adjust glucocorticoid dose by approximately 10‑20% upward for under-representation, downward for over-representation, or maintain if stable; schedule reassessment in 3 months or sooner if symptoms change.

## Clinical Guardrails / Mimics / Pitfalls
Do not rely solely on ACTH or cortisol levels for dose adjustments; avoid synthetic long‑acting glucocorticoids in children; refrain from making dose changes based on a single abnormal measurement; watch for signs of adrenal crisis (vomiting, lethargy, hypotension) which require stress dosing, not routine adjustment.

## Concrete Clinical Example
A 6‑year‑old with PAI on hydrocortisone 8 mg/m²/d divided TID shows growth velocity dropping from 5 cm/yr to 3 cm/yr, weight plateau, and mild fatigue. After assessment, dose is increased to 9 mg/m²/d; at 3‑month follow‑up, growth velocity improves to 4.5 cm/yr and energy normalizes.

**Source:** Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, DOI:10.1210/jc.2015-1710